nodes	percent_of_prediction	percent_of_DWPC	metapath
Fluocinolone Acetonide—PLA2G4A—Epirubicin—ovarian cancer	0.699	1	CbGbCtD
Fluocinolone Acetonide—SERPINA6—oviduct—ovarian cancer	0.0163	0.214	CbGeAlD
Fluocinolone Acetonide—PLA2G4A—myometrium—ovarian cancer	0.00525	0.0689	CbGeAlD
Fluocinolone Acetonide—PLA2G4A—uterine cervix—ovarian cancer	0.00409	0.0536	CbGeAlD
Fluocinolone Acetonide—PLA2G4A—decidua—ovarian cancer	0.00389	0.0511	CbGeAlD
Fluocinolone Acetonide—PLA2G4A—endometrium—ovarian cancer	0.00369	0.0485	CbGeAlD
Fluocinolone Acetonide—PLA2G4A—female reproductive system—ovarian cancer	0.00306	0.0402	CbGeAlD
Fluocinolone Acetonide—SERPINA6—female reproductive system—ovarian cancer	0.00305	0.04	CbGeAlD
Fluocinolone Acetonide—PLA2G4A—bone marrow—ovarian cancer	0.00289	0.0379	CbGeAlD
Fluocinolone Acetonide—SERPINA6—bone marrow—ovarian cancer	0.00288	0.0378	CbGeAlD
Fluocinolone Acetonide—PLA2G4A—female gonad—ovarian cancer	0.00278	0.0366	CbGeAlD
Fluocinolone Acetonide—PLA2G4A—vagina—ovarian cancer	0.00277	0.0363	CbGeAlD
Fluocinolone Acetonide—PLA2G4A—testis—ovarian cancer	0.00247	0.0324	CbGeAlD
Fluocinolone Acetonide—NR3C1—myometrium—ovarian cancer	0.00229	0.0301	CbGeAlD
Fluocinolone Acetonide—NR3C1—embryo—ovarian cancer	0.0022	0.0289	CbGeAlD
Fluocinolone Acetonide—NR3C1—epithelium—ovarian cancer	0.0018	0.0236	CbGeAlD
Fluocinolone Acetonide—PLA2G4A—lymph node—ovarian cancer	0.00179	0.0235	CbGeAlD
Fluocinolone Acetonide—NR3C1—uterine cervix—ovarian cancer	0.00178	0.0234	CbGeAlD
Fluocinolone Acetonide—NR3C1—decidua—ovarian cancer	0.0017	0.0223	CbGeAlD
Fluocinolone Acetonide—NR3C1—endometrium—ovarian cancer	0.00161	0.0212	CbGeAlD
Fluocinolone Acetonide—NR3C1—gonad—ovarian cancer	0.00149	0.0196	CbGeAlD
Fluocinolone Acetonide—NR3C1—uterus—ovarian cancer	0.00149	0.0195	CbGeAlD
Fluocinolone Acetonide—NR3C1—female reproductive system—ovarian cancer	0.00133	0.0175	CbGeAlD
Fluocinolone Acetonide—NR3C1—bone marrow—ovarian cancer	0.00126	0.0165	CbGeAlD
Fluocinolone Acetonide—NR3C1—female gonad—ovarian cancer	0.00121	0.0159	CbGeAlD
Fluocinolone Acetonide—NR3C1—vagina—ovarian cancer	0.00121	0.0158	CbGeAlD
Fluocinolone Acetonide—NR3C1—testis—ovarian cancer	0.00108	0.0141	CbGeAlD
Fluocinolone Acetonide—NR3C1—lymph node—ovarian cancer	0.000781	0.0102	CbGeAlD
Fluocinolone Acetonide—Fluticasone Propionate—PGR—ovarian cancer	0.000774	0.228	CrCbGaD
Fluocinolone Acetonide—Betamethasone—PGR—ovarian cancer	0.000709	0.209	CrCbGaD
Fluocinolone Acetonide—Folliculitis—Doxorubicin—ovarian cancer	0.000686	0.00416	CcSEcCtD
Fluocinolone Acetonide—Connective tissue disorder—Melphalan—ovarian cancer	0.000685	0.00415	CcSEcCtD
Fluocinolone Acetonide—Infestation NOS—Vinorelbine—ovarian cancer	0.000678	0.00411	CcSEcCtD
Fluocinolone Acetonide—Infestation—Vinorelbine—ovarian cancer	0.000678	0.00411	CcSEcCtD
Fluocinolone Acetonide—Eye pain—Paclitaxel—ovarian cancer	0.000656	0.00397	CcSEcCtD
Fluocinolone Acetonide—Mediastinal disorder—Topotecan—ovarian cancer	0.000641	0.00389	CcSEcCtD
Fluocinolone Acetonide—Alopecia—Topotecan—ovarian cancer	0.000629	0.00381	CcSEcCtD
Fluocinolone Acetonide—Mediastinal disorder—Melphalan—ovarian cancer	0.000628	0.00381	CcSEcCtD
Fluocinolone Acetonide—Visual disturbance—Paclitaxel—ovarian cancer	0.000625	0.00378	CcSEcCtD
Fluocinolone Acetonide—Malnutrition—Topotecan—ovarian cancer	0.00062	0.00375	CcSEcCtD
Fluocinolone Acetonide—Alopecia—Melphalan—ovarian cancer	0.000616	0.00373	CcSEcCtD
Fluocinolone Acetonide—Hypoglycaemia—Paclitaxel—ovarian cancer	0.000607	0.00368	CcSEcCtD
Fluocinolone Acetonide—Back pain—Topotecan—ovarian cancer	0.000599	0.00363	CcSEcCtD
Fluocinolone Acetonide—Otitis media—Epirubicin—ovarian cancer	0.000599	0.00363	CcSEcCtD
Fluocinolone Acetonide—Connective tissue disorder—Vinorelbine—ovarian cancer	0.000598	0.00362	CcSEcCtD
Fluocinolone Acetonide—Pain in extremity—Paclitaxel—ovarian cancer	0.000592	0.00359	CcSEcCtD
Fluocinolone Acetonide—Abscess—Epirubicin—ovarian cancer	0.000589	0.00357	CcSEcCtD
Fluocinolone Acetonide—Rash pustular—Epirubicin—ovarian cancer	0.000585	0.00354	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—AGE/RAGE pathway—SOD1—ovarian cancer	0.000569	0.0101	CbGpPWpGaD
Fluocinolone Acetonide—Infection—Chlorambucil—ovarian cancer	0.000564	0.00342	CcSEcCtD
Fluocinolone Acetonide—Otitis media—Doxorubicin—ovarian cancer	0.000554	0.00336	CcSEcCtD
Fluocinolone Acetonide—Mediastinal disorder—Vinorelbine—ovarian cancer	0.000549	0.00332	CcSEcCtD
Fluocinolone Acetonide—Abscess—Doxorubicin—ovarian cancer	0.000545	0.0033	CcSEcCtD
Fluocinolone Acetonide—Rash pustular—Doxorubicin—ovarian cancer	0.000541	0.00328	CcSEcCtD
Fluocinolone Acetonide—Cough—Topotecan—ovarian cancer	0.000541	0.00328	CcSEcCtD
Fluocinolone Acetonide—Alopecia—Vinorelbine—ovarian cancer	0.000538	0.00326	CcSEcCtD
Fluocinolone Acetonide—Erythema—Vinorelbine—ovarian cancer	0.00053	0.00321	CcSEcCtD
Fluocinolone Acetonide—Malnutrition—Vinorelbine—ovarian cancer	0.00053	0.00321	CcSEcCtD
Fluocinolone Acetonide—Visual disturbance—Docetaxel—ovarian cancer	0.00053	0.00321	CcSEcCtD
Fluocinolone Acetonide—Cough—Melphalan—ovarian cancer	0.000529	0.00321	CcSEcCtD
Fluocinolone Acetonide—Nasopharyngitis—Paclitaxel—ovarian cancer	0.000529	0.00321	CcSEcCtD
Fluocinolone Acetonide—Arthralgia—Topotecan—ovarian cancer	0.000528	0.0032	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—ATF3—ovarian cancer	0.000524	0.00932	CbGpPWpGaD
Fluocinolone Acetonide—Viral infection—Epirubicin—ovarian cancer	0.000516	0.00313	CcSEcCtD
Fluocinolone Acetonide—Back pain—Vinorelbine—ovarian cancer	0.000513	0.00311	CcSEcCtD
Fluocinolone Acetonide—Influenza—Paclitaxel—ovarian cancer	0.000512	0.0031	CcSEcCtD
Fluocinolone Acetonide—Lacrimation increased—Epirubicin—ovarian cancer	0.000506	0.00307	CcSEcCtD
Fluocinolone Acetonide—Herpes simplex—Epirubicin—ovarian cancer	0.000506	0.00307	CcSEcCtD
Fluocinolone Acetonide—Infection—Topotecan—ovarian cancer	0.000502	0.00304	CcSEcCtD
Fluocinolone Acetonide—Pain in extremity—Docetaxel—ovarian cancer	0.000502	0.00304	CcSEcCtD
Fluocinolone Acetonide—Nervous system disorder—Topotecan—ovarian cancer	0.000496	0.003	CcSEcCtD
Fluocinolone Acetonide—Oedema—Melphalan—ovarian cancer	0.000495	0.003	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Platelet homeostasis—PPP2R1A—ovarian cancer	0.000495	0.00881	CbGpPWpGaD
Fluocinolone Acetonide—Infection—Melphalan—ovarian cancer	0.000492	0.00298	CcSEcCtD
Fluocinolone Acetonide—Gastrointestinal disorder—Chlorambucil—ovarian cancer	0.00049	0.00297	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Glucocorticoid receptor regulatory network—SMARCA4—ovarian cancer	0.000488	0.00869	CbGpPWpGaD
Fluocinolone Acetonide—Pain—Chlorambucil—ovarian cancer	0.000486	0.00294	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Adipogenesis—RBL2—ovarian cancer	0.000484	0.00862	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Opioid Signalling—PPP2R1A—ovarian cancer	0.00048	0.00855	CbGpPWpGaD
Fluocinolone Acetonide—Viral infection—Doxorubicin—ovarian cancer	0.000478	0.00289	CcSEcCtD
Fluocinolone Acetonide—Vertigo—Vinorelbine—ovarian cancer	0.000476	0.00289	CcSEcCtD
Fluocinolone Acetonide—Upper respiratory tract infection—Paclitaxel—ovarian cancer	0.000476	0.00288	CcSEcCtD
Fluocinolone Acetonide—Neck pain—Epirubicin—ovarian cancer	0.000472	0.00286	CcSEcCtD
Fluocinolone Acetonide—Herpes simplex—Doxorubicin—ovarian cancer	0.000468	0.00284	CcSEcCtD
Fluocinolone Acetonide—Lacrimation increased—Doxorubicin—ovarian cancer	0.000468	0.00284	CcSEcCtD
Fluocinolone Acetonide—Cough—Vinorelbine—ovarian cancer	0.000463	0.0028	CcSEcCtD
Fluocinolone Acetonide—Dermatitis contact—Epirubicin—ovarian cancer	0.000461	0.00279	CcSEcCtD
Fluocinolone Acetonide—Musculoskeletal discomfort—Topotecan—ovarian cancer	0.000461	0.00279	CcSEcCtD
Fluocinolone Acetonide—Infestation—Paclitaxel—ovarian cancer	0.000456	0.00276	CcSEcCtD
Fluocinolone Acetonide—Infestation NOS—Paclitaxel—ovarian cancer	0.000456	0.00276	CcSEcCtD
Fluocinolone Acetonide—Arthralgia—Vinorelbine—ovarian cancer	0.000451	0.00273	CcSEcCtD
Fluocinolone Acetonide—Musculoskeletal discomfort—Melphalan—ovarian cancer	0.000451	0.00273	CcSEcCtD
Fluocinolone Acetonide—Body temperature increased—Chlorambucil—ovarian cancer	0.000449	0.00272	CcSEcCtD
Fluocinolone Acetonide—Nasopharyngitis—Docetaxel—ovarian cancer	0.000449	0.00272	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Nuclear Receptors—ESR1—ovarian cancer	0.000441	0.00785	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Signaling events mediated by HDAC Class II—ESR1—ovarian cancer	0.000441	0.00785	CbGpPWpGaD
Fluocinolone Acetonide—Neck pain—Doxorubicin—ovarian cancer	0.000437	0.00265	CcSEcCtD
Fluocinolone Acetonide—Gastrointestinal disorder—Topotecan—ovarian cancer	0.000437	0.00264	CcSEcCtD
Fluocinolone Acetonide—Pain—Topotecan—ovarian cancer	0.000432	0.00262	CcSEcCtD
Fluocinolone Acetonide—Dry eye—Epirubicin—ovarian cancer	0.000431	0.00261	CcSEcCtD
Fluocinolone Acetonide—Infection—Vinorelbine—ovarian cancer	0.00043	0.0026	CcSEcCtD
Fluocinolone Acetonide—Sinusitis—Paclitaxel—ovarian cancer	0.000428	0.00259	CcSEcCtD
Fluocinolone Acetonide—Gastrointestinal disorder—Melphalan—ovarian cancer	0.000427	0.00259	CcSEcCtD
Fluocinolone Acetonide—Dermatitis contact—Doxorubicin—ovarian cancer	0.000426	0.00258	CcSEcCtD
Fluocinolone Acetonide—Nervous system disorder—Vinorelbine—ovarian cancer	0.000424	0.00257	CcSEcCtD
Fluocinolone Acetonide—Pain—Melphalan—ovarian cancer	0.000423	0.00257	CcSEcCtD
Fluocinolone Acetonide—Hypersensitivity—Chlorambucil—ovarian cancer	0.000419	0.00254	CcSEcCtD
Fluocinolone Acetonide—Dexamethasone—PGR—ovarian cancer	0.000412	0.121	CrCbGaD
Fluocinolone Acetonide—Rhinitis—Paclitaxel—ovarian cancer	0.000411	0.00249	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Serotonin Receptor 4/6/7 and NR3C Signaling—MAPK3—ovarian cancer	0.00041	0.00731	CbGpPWpGaD
Fluocinolone Acetonide—Connective tissue disorder—Paclitaxel—ovarian cancer	0.000402	0.00244	CcSEcCtD
Fluocinolone Acetonide—Pruritus—Chlorambucil—ovarian cancer	0.000402	0.00243	CcSEcCtD
Fluocinolone Acetonide—Body temperature increased—Topotecan—ovarian cancer	0.0004	0.00242	CcSEcCtD
Fluocinolone Acetonide—Dry eye—Doxorubicin—ovarian cancer	0.000398	0.00241	CcSEcCtD
Fluocinolone Acetonide—Visual impairment—Paclitaxel—ovarian cancer	0.000395	0.00239	CcSEcCtD
Fluocinolone Acetonide—Musculoskeletal discomfort—Vinorelbine—ovarian cancer	0.000394	0.00239	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Serotonin Receptor 4/6/7 and NR3C Signaling—MAPK1—ovarian cancer	0.000391	0.00695	CbGpPWpGaD
Fluocinolone Acetonide—Diarrhoea—Chlorambucil—ovarian cancer	0.000389	0.00235	CcSEcCtD
Fluocinolone Acetonide—Infestation—Docetaxel—ovarian cancer	0.000387	0.00234	CcSEcCtD
Fluocinolone Acetonide—Infestation NOS—Docetaxel—ovarian cancer	0.000387	0.00234	CcSEcCtD
Fluocinolone Acetonide—Dexamethasone—CYP1B1—ovarian cancer	0.000385	0.113	CrCbGaD
Fluocinolone Acetonide—PLA2G4A—Ca-dependent events—MAPK1—ovarian cancer	0.000383	0.00682	CbGpPWpGaD
Fluocinolone Acetonide—Eye disorder—Paclitaxel—ovarian cancer	0.000383	0.00232	CcSEcCtD
Fluocinolone Acetonide—Eczema—Epirubicin—ovarian cancer	0.000377	0.00228	CcSEcCtD
Fluocinolone Acetonide—Eye pain—Epirubicin—ovarian cancer	0.000375	0.00227	CcSEcCtD
Fluocinolone Acetonide—Gastrointestinal disorder—Vinorelbine—ovarian cancer	0.000373	0.00226	CcSEcCtD
Fluocinolone Acetonide—Hypersensitivity—Topotecan—ovarian cancer	0.000373	0.00226	CcSEcCtD
Fluocinolone Acetonide—Pain—Vinorelbine—ovarian cancer	0.00037	0.00224	CcSEcCtD
Fluocinolone Acetonide—Mediastinal disorder—Paclitaxel—ovarian cancer	0.000369	0.00224	CcSEcCtD
Fluocinolone Acetonide—Hypersensitivity—Melphalan—ovarian cancer	0.000365	0.00221	CcSEcCtD
Fluocinolone Acetonide—Alopecia—Paclitaxel—ovarian cancer	0.000362	0.00219	CcSEcCtD
Fluocinolone Acetonide—Vomiting—Chlorambucil—ovarian cancer	0.000361	0.00219	CcSEcCtD
Fluocinolone Acetonide—Mental disorder—Paclitaxel—ovarian cancer	0.000359	0.00217	CcSEcCtD
Fluocinolone Acetonide—Pruritus—Topotecan—ovarian cancer	0.000358	0.00217	CcSEcCtD
Fluocinolone Acetonide—Erythema—Paclitaxel—ovarian cancer	0.000357	0.00216	CcSEcCtD
Fluocinolone Acetonide—Malnutrition—Paclitaxel—ovarian cancer	0.000357	0.00216	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—p38 MAPK Signaling Pathway—MYC—ovarian cancer	0.000354	0.00631	CbGpPWpGaD
Fluocinolone Acetonide—Pruritus—Melphalan—ovarian cancer	0.00035	0.00212	CcSEcCtD
Fluocinolone Acetonide—Dysgeusia—Paclitaxel—ovarian cancer	0.000349	0.00212	CcSEcCtD
Fluocinolone Acetonide—Eczema—Doxorubicin—ovarian cancer	0.000348	0.00211	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Nuclear Receptor transcription pathway—ESR1—ovarian cancer	0.000348	0.0062	CbGpPWpGaD
Fluocinolone Acetonide—Rhinitis—Docetaxel—ovarian cancer	0.000348	0.00211	CcSEcCtD
Fluocinolone Acetonide—Eye pain—Doxorubicin—ovarian cancer	0.000347	0.0021	CcSEcCtD
Fluocinolone Acetonide—Hypoglycaemia—Epirubicin—ovarian cancer	0.000347	0.0021	CcSEcCtD
Fluocinolone Acetonide—Diarrhoea—Topotecan—ovarian cancer	0.000346	0.0021	CcSEcCtD
Fluocinolone Acetonide—Fluticasone furoate—ABCB1—ovarian cancer	0.000345	0.102	CrCbGaD
Fluocinolone Acetonide—Back pain—Paclitaxel—ovarian cancer	0.000345	0.00209	CcSEcCtD
Fluocinolone Acetonide—Body temperature increased—Vinorelbine—ovarian cancer	0.000342	0.00207	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—PDGF Pathway—STAT3—ovarian cancer	0.000342	0.00608	CbGpPWpGaD
Fluocinolone Acetonide—Connective tissue disorder—Docetaxel—ovarian cancer	0.000341	0.00207	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—PDGFR-beta signaling pathway—PPP2R1A—ovarian cancer	0.000339	0.00604	CbGpPWpGaD
Fluocinolone Acetonide—Diarrhoea—Melphalan—ovarian cancer	0.000339	0.00205	CcSEcCtD
Fluocinolone Acetonide—Diplopia—Epirubicin—ovarian cancer	0.000338	0.00205	CcSEcCtD
Fluocinolone Acetonide—Pain in extremity—Epirubicin—ovarian cancer	0.000338	0.00205	CcSEcCtD
Fluocinolone Acetonide—Nausea—Chlorambucil—ovarian cancer	0.000337	0.00204	CcSEcCtD
Fluocinolone Acetonide—Vision blurred—Paclitaxel—ovarian cancer	0.000336	0.00204	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—AGE/RAGE pathway—MMP2—ovarian cancer	0.000336	0.00597	CbGpPWpGaD
Fluocinolone Acetonide—Visual impairment—Docetaxel—ovarian cancer	0.000335	0.00203	CcSEcCtD
Fluocinolone Acetonide—Dizziness—Topotecan—ovarian cancer	0.000334	0.00203	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—PDGF Pathway—MAPK3—ovarian cancer	0.000326	0.00581	CbGpPWpGaD
Fluocinolone Acetonide—Eye disorder—Docetaxel—ovarian cancer	0.000324	0.00197	CcSEcCtD
Fluocinolone Acetonide—Vomiting—Topotecan—ovarian cancer	0.000322	0.00195	CcSEcCtD
Fluocinolone Acetonide—Hypoglycaemia—Doxorubicin—ovarian cancer	0.000321	0.00194	CcSEcCtD
Fluocinolone Acetonide—Vertigo—Paclitaxel—ovarian cancer	0.00032	0.00194	CcSEcCtD
Fluocinolone Acetonide—Rash—Topotecan—ovarian cancer	0.000319	0.00193	CcSEcCtD
Fluocinolone Acetonide—Hypersensitivity—Vinorelbine—ovarian cancer	0.000319	0.00193	CcSEcCtD
Fluocinolone Acetonide—Dermatitis—Topotecan—ovarian cancer	0.000319	0.00193	CcSEcCtD
Fluocinolone Acetonide—Headache—Topotecan—ovarian cancer	0.000317	0.00192	CcSEcCtD
Fluocinolone Acetonide—Vomiting—Melphalan—ovarian cancer	0.000315	0.00191	CcSEcCtD
Fluocinolone Acetonide—Diplopia—Doxorubicin—ovarian cancer	0.000313	0.0019	CcSEcCtD
Fluocinolone Acetonide—Pain in extremity—Doxorubicin—ovarian cancer	0.000313	0.0019	CcSEcCtD
Fluocinolone Acetonide—Mediastinal disorder—Docetaxel—ovarian cancer	0.000313	0.0019	CcSEcCtD
Fluocinolone Acetonide—Rash—Melphalan—ovarian cancer	0.000312	0.00189	CcSEcCtD
Fluocinolone Acetonide—Dermatitis—Melphalan—ovarian cancer	0.000312	0.00189	CcSEcCtD
Fluocinolone Acetonide—Cough—Paclitaxel—ovarian cancer	0.000311	0.00188	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—PDGF Pathway—MAPK1—ovarian cancer	0.000311	0.00553	CbGpPWpGaD
Fluocinolone Acetonide—Alopecia—Docetaxel—ovarian cancer	0.000307	0.00186	CcSEcCtD
Fluocinolone Acetonide—Pruritus—Vinorelbine—ovarian cancer	0.000306	0.00185	CcSEcCtD
Fluocinolone Acetonide—Mental disorder—Docetaxel—ovarian cancer	0.000304	0.00184	CcSEcCtD
Fluocinolone Acetonide—Arthralgia—Paclitaxel—ovarian cancer	0.000304	0.00184	CcSEcCtD
Fluocinolone Acetonide—Nasopharyngitis—Epirubicin—ovarian cancer	0.000303	0.00183	CcSEcCtD
Fluocinolone Acetonide—Malnutrition—Docetaxel—ovarian cancer	0.000302	0.00183	CcSEcCtD
Fluocinolone Acetonide—Erythema—Docetaxel—ovarian cancer	0.000302	0.00183	CcSEcCtD
Fluocinolone Acetonide—Nausea—Topotecan—ovarian cancer	0.0003	0.00182	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—GADD45A—ovarian cancer	0.000299	0.00533	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Platelet activation, signaling and aggregation—SPARC—ovarian cancer	0.000298	0.0053	CbGpPWpGaD
Fluocinolone Acetonide—Diarrhoea—Vinorelbine—ovarian cancer	0.000296	0.00179	CcSEcCtD
Fluocinolone Acetonide—Dysgeusia—Docetaxel—ovarian cancer	0.000296	0.00179	CcSEcCtD
Fluocinolone Acetonide—Nausea—Melphalan—ovarian cancer	0.000294	0.00178	CcSEcCtD
Fluocinolone Acetonide—Influenza—Epirubicin—ovarian cancer	0.000293	0.00177	CcSEcCtD
Fluocinolone Acetonide—Back pain—Docetaxel—ovarian cancer	0.000292	0.00177	CcSEcCtD
Fluocinolone Acetonide—Oedema—Paclitaxel—ovarian cancer	0.000291	0.00176	CcSEcCtD
Fluocinolone Acetonide—Infection—Paclitaxel—ovarian cancer	0.000289	0.00175	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Adipogenesis—GADD45A—ovarian cancer	0.000288	0.00513	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—RAD51C—ovarian cancer	0.000287	0.00512	CbGpPWpGaD
Fluocinolone Acetonide—Dizziness—Vinorelbine—ovarian cancer	0.000286	0.00173	CcSEcCtD
Fluocinolone Acetonide—Nervous system disorder—Paclitaxel—ovarian cancer	0.000285	0.00173	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Signaling mediated by p38-alpha and p38-beta—TP53—ovarian cancer	0.000284	0.00506	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—PLC beta mediated events—MAPK1—ovarian cancer	0.000282	0.00502	CbGpPWpGaD
Fluocinolone Acetonide—Nasopharyngitis—Doxorubicin—ovarian cancer	0.00028	0.0017	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—p38 MAPK Signaling Pathway—HRAS—ovarian cancer	0.000278	0.00495	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—G-protein mediated events—MAPK1—ovarian cancer	0.000277	0.00493	CbGpPWpGaD
Fluocinolone Acetonide—Methylprednisolone—ABCB1—ovarian cancer	0.000275	0.0811	CrCbGaD
Fluocinolone Acetonide—Vomiting—Vinorelbine—ovarian cancer	0.000275	0.00167	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—CHEK2—ovarian cancer	0.000274	0.00487	CbGpPWpGaD
Fluocinolone Acetonide—Rash—Vinorelbine—ovarian cancer	0.000273	0.00165	CcSEcCtD
Fluocinolone Acetonide—Dermatitis—Vinorelbine—ovarian cancer	0.000272	0.00165	CcSEcCtD
Fluocinolone Acetonide—Upper respiratory tract infection—Epirubicin—ovarian cancer	0.000272	0.00165	CcSEcCtD
Fluocinolone Acetonide—Headache—Vinorelbine—ovarian cancer	0.000271	0.00164	CcSEcCtD
Fluocinolone Acetonide—Influenza—Doxorubicin—ovarian cancer	0.000271	0.00164	CcSEcCtD
Fluocinolone Acetonide—NR3C1—AP-1 transcription factor network—ESR1—ovarian cancer	0.00027	0.00481	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Transcription factor regulation in adipogenesis—IL6—ovarian cancer	0.000267	0.00475	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—AGE/RAGE pathway—CASP3—ovarian cancer	0.000267	0.00475	CbGpPWpGaD
Fluocinolone Acetonide—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	0.000265	0.00161	CcSEcCtD
Fluocinolone Acetonide—Cough—Docetaxel—ovarian cancer	0.000264	0.0016	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Endoderm Differentiation—APC—ovarian cancer	0.000262	0.00466	CbGpPWpGaD
Fluocinolone Acetonide—Infestation—Epirubicin—ovarian cancer	0.000261	0.00158	CcSEcCtD
Fluocinolone Acetonide—Infestation NOS—Epirubicin—ovarian cancer	0.000261	0.00158	CcSEcCtD
Fluocinolone Acetonide—Arthralgia—Docetaxel—ovarian cancer	0.000257	0.00156	CcSEcCtD
Fluocinolone Acetonide—Nausea—Vinorelbine—ovarian cancer	0.000257	0.00156	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—BRCA1—ovarian cancer	0.000256	0.00456	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—AGE/RAGE pathway—MMP9—ovarian cancer	0.000252	0.00449	CbGpPWpGaD
Fluocinolone Acetonide—Upper respiratory tract infection—Doxorubicin—ovarian cancer	0.000252	0.00152	CcSEcCtD
Fluocinolone Acetonide—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.000251	0.00152	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—PDGF Pathway—HRAS—ovarian cancer	0.000249	0.00444	CbGpPWpGaD
Fluocinolone Acetonide—Pain—Paclitaxel—ovarian cancer	0.000249	0.00151	CcSEcCtD
Fluocinolone Acetonide—Oedema—Docetaxel—ovarian cancer	0.000247	0.00149	CcSEcCtD
Fluocinolone Acetonide—Infection—Docetaxel—ovarian cancer	0.000245	0.00148	CcSEcCtD
Fluocinolone Acetonide—Sinusitis—Epirubicin—ovarian cancer	0.000245	0.00148	CcSEcCtD
Fluocinolone Acetonide—Nervous system disorder—Docetaxel—ovarian cancer	0.000242	0.00147	CcSEcCtD
Fluocinolone Acetonide—Infestation—Doxorubicin—ovarian cancer	0.000241	0.00146	CcSEcCtD
Fluocinolone Acetonide—Infestation NOS—Doxorubicin—ovarian cancer	0.000241	0.00146	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—ESR1—ovarian cancer	0.000241	0.00428	CbGpPWpGaD
Fluocinolone Acetonide—Rhinitis—Epirubicin—ovarian cancer	0.000235	0.00142	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—BRCA2—ovarian cancer	0.000232	0.00413	CbGpPWpGaD
Fluocinolone Acetonide—Connective tissue disorder—Epirubicin—ovarian cancer	0.00023	0.00139	CcSEcCtD
Fluocinolone Acetonide—Body temperature increased—Paclitaxel—ovarian cancer	0.00023	0.00139	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Metabolism of lipids and lipoproteins—PPP1CC—ovarian cancer	0.000229	0.00407	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Fc-epsilon receptor I signaling in mast cells—MAPK3—ovarian cancer	0.000228	0.00406	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—PDGFR-beta signaling pathway—PIK3CG—ovarian cancer	0.000227	0.00405	CbGpPWpGaD
Fluocinolone Acetonide—Sinusitis—Doxorubicin—ovarian cancer	0.000226	0.00137	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Generic Transcription Pathway—NR5A1—ovarian cancer	0.000226	0.00403	CbGpPWpGaD
Fluocinolone Acetonide—Visual impairment—Epirubicin—ovarian cancer	0.000226	0.00137	CcSEcCtD
Fluocinolone Acetonide—Musculoskeletal discomfort—Docetaxel—ovarian cancer	0.000225	0.00136	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—CCNE1—ovarian cancer	0.000225	0.004	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—ABCB1—ovarian cancer	0.000225	0.004	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—AGE/RAGE pathway—STAT3—ovarian cancer	0.000224	0.00399	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Endothelins—MAPK3—ovarian cancer	0.000222	0.00396	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—TYMS—ovarian cancer	0.000221	0.00393	CbGpPWpGaD
Fluocinolone Acetonide—Eye disorder—Epirubicin—ovarian cancer	0.000219	0.00133	CcSEcCtD
Fluocinolone Acetonide—Rhinitis—Doxorubicin—ovarian cancer	0.000217	0.00132	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Fc-epsilon receptor I signaling in mast cells—MAPK1—ovarian cancer	0.000217	0.00387	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Platelet activation, signaling and aggregation—SOD1—ovarian cancer	0.000216	0.00385	CbGpPWpGaD
Fluocinolone Acetonide—Hypersensitivity—Paclitaxel—ovarian cancer	0.000214	0.0013	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—AGE/RAGE pathway—MAPK3—ovarian cancer	0.000214	0.00381	CbGpPWpGaD
Fluocinolone Acetonide—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.000213	0.00129	CcSEcCtD
Fluocinolone Acetonide—Connective tissue disorder—Doxorubicin—ovarian cancer	0.000213	0.00129	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Endothelins—MAPK1—ovarian cancer	0.000212	0.00377	CbGpPWpGaD
Fluocinolone Acetonide—Mediastinal disorder—Epirubicin—ovarian cancer	0.000211	0.00128	CcSEcCtD
Fluocinolone Acetonide—Pain—Docetaxel—ovarian cancer	0.000211	0.00128	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Phospholipid metabolism—PIK3CG—ovarian cancer	0.00021	0.00374	CbGpPWpGaD
Fluocinolone Acetonide—Visual impairment—Doxorubicin—ovarian cancer	0.000209	0.00126	CcSEcCtD
Fluocinolone Acetonide—Alopecia—Epirubicin—ovarian cancer	0.000207	0.00125	CcSEcCtD
Fluocinolone Acetonide—Pruritus—Paclitaxel—ovarian cancer	0.000206	0.00125	CcSEcCtD
Fluocinolone Acetonide—Mental disorder—Epirubicin—ovarian cancer	0.000205	0.00124	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—AGE/RAGE pathway—MAPK1—ovarian cancer	0.000204	0.00363	CbGpPWpGaD
Fluocinolone Acetonide—Malnutrition—Epirubicin—ovarian cancer	0.000204	0.00123	CcSEcCtD
Fluocinolone Acetonide—Erythema—Epirubicin—ovarian cancer	0.000204	0.00123	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—AGE/RAGE pathway—EGFR—ovarian cancer	0.000204	0.00363	CbGpPWpGaD
Fluocinolone Acetonide—Eye disorder—Doxorubicin—ovarian cancer	0.000202	0.00123	CcSEcCtD
Fluocinolone Acetonide—Dysgeusia—Epirubicin—ovarian cancer	0.0002	0.00121	CcSEcCtD
Fluocinolone Acetonide—Diarrhoea—Paclitaxel—ovarian cancer	0.000199	0.00121	CcSEcCtD
Fluocinolone Acetonide—Back pain—Epirubicin—ovarian cancer	0.000197	0.00119	CcSEcCtD
Fluocinolone Acetonide—Mediastinal disorder—Doxorubicin—ovarian cancer	0.000195	0.00118	CcSEcCtD
Fluocinolone Acetonide—Body temperature increased—Docetaxel—ovarian cancer	0.000195	0.00118	CcSEcCtD
Fluocinolone Acetonide—Prednisolone—ABCB1—ovarian cancer	0.000194	0.0571	CrCbGaD
Fluocinolone Acetonide—Dizziness—Paclitaxel—ovarian cancer	0.000192	0.00117	CcSEcCtD
Fluocinolone Acetonide—Vision blurred—Epirubicin—ovarian cancer	0.000192	0.00116	CcSEcCtD
Fluocinolone Acetonide—Alopecia—Doxorubicin—ovarian cancer	0.000191	0.00116	CcSEcCtD
Fluocinolone Acetonide—Betamethasone—ABCB1—ovarian cancer	0.00019	0.056	CrCbGaD
Fluocinolone Acetonide—Mental disorder—Doxorubicin—ovarian cancer	0.00019	0.00115	CcSEcCtD
Fluocinolone Acetonide—Malnutrition—Doxorubicin—ovarian cancer	0.000189	0.00114	CcSEcCtD
Fluocinolone Acetonide—Erythema—Doxorubicin—ovarian cancer	0.000189	0.00114	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Fc-epsilon receptor I signaling in mast cells—PIK3CA—ovarian cancer	0.000188	0.00335	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—AP-1 transcription factor network—CXCL8—ovarian cancer	0.000188	0.00335	CbGpPWpGaD
Fluocinolone Acetonide—Vomiting—Paclitaxel—ovarian cancer	0.000185	0.00112	CcSEcCtD
Fluocinolone Acetonide—Dysgeusia—Doxorubicin—ovarian cancer	0.000185	0.00112	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Phospholipid metabolism—PIK3CD—ovarian cancer	0.000185	0.00329	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—AP-1 transcription factor network—CDKN1B—ovarian cancer	0.000184	0.00327	CbGpPWpGaD
Fluocinolone Acetonide—Rash—Paclitaxel—ovarian cancer	0.000183	0.00111	CcSEcCtD
Fluocinolone Acetonide—Dermatitis—Paclitaxel—ovarian cancer	0.000183	0.00111	CcSEcCtD
Fluocinolone Acetonide—Vertigo—Epirubicin—ovarian cancer	0.000183	0.00111	CcSEcCtD
Fluocinolone Acetonide—Back pain—Doxorubicin—ovarian cancer	0.000182	0.00111	CcSEcCtD
Fluocinolone Acetonide—Headache—Paclitaxel—ovarian cancer	0.000182	0.0011	CcSEcCtD
Fluocinolone Acetonide—Hypersensitivity—Docetaxel—ovarian cancer	0.000182	0.0011	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Metabolism—NME2—ovarian cancer	0.000181	0.00322	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—AP-1 transcription factor network—IL2—ovarian cancer	0.00018	0.0032	CbGpPWpGaD
Fluocinolone Acetonide—Cough—Epirubicin—ovarian cancer	0.000178	0.00108	CcSEcCtD
Fluocinolone Acetonide—Vision blurred—Doxorubicin—ovarian cancer	0.000178	0.00108	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Endoderm Differentiation—CTNNB1—ovarian cancer	0.000178	0.00316	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—AP-1 transcription factor network—CCND1—ovarian cancer	0.000175	0.00312	CbGpPWpGaD
Fluocinolone Acetonide—Pruritus—Docetaxel—ovarian cancer	0.000174	0.00106	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Fc-epsilon receptor I signaling in mast cells—HRAS—ovarian cancer	0.000174	0.0031	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—PDGFR-beta signaling pathway—PIK3CB—ovarian cancer	0.000174	0.0031	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—AP-1 transcription factor network—CTNNB1—ovarian cancer	0.000174	0.00309	CbGpPWpGaD
Fluocinolone Acetonide—Arthralgia—Epirubicin—ovarian cancer	0.000174	0.00105	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Opioid Signalling—MAPK1—ovarian cancer	0.000173	0.00308	CbGpPWpGaD
Fluocinolone Acetonide—Nausea—Paclitaxel—ovarian cancer	0.000173	0.00105	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—ESR1—ovarian cancer	0.000171	0.00305	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—AP-1 transcription factor network—MMP9—ovarian cancer	0.00017	0.00303	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Endothelins—HRAS—ovarian cancer	0.00017	0.00302	CbGpPWpGaD
Fluocinolone Acetonide—Vertigo—Doxorubicin—ovarian cancer	0.000169	0.00103	CcSEcCtD
Fluocinolone Acetonide—NR3C1—AP-1 transcription factor network—PTEN—ovarian cancer	0.000169	0.00301	CbGpPWpGaD
Fluocinolone Acetonide—Diarrhoea—Docetaxel—ovarian cancer	0.000169	0.00102	CcSEcCtD
Fluocinolone Acetonide—Oedema—Epirubicin—ovarian cancer	0.000166	0.00101	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Glucocorticoid receptor regulatory network—CXCL8—ovarian cancer	0.000166	0.00295	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—HSD17B6—ovarian cancer	0.000165	0.00294	CbGpPWpGaD
Fluocinolone Acetonide—Infection—Epirubicin—ovarian cancer	0.000165	0.001	CcSEcCtD
Fluocinolone Acetonide—Cough—Doxorubicin—ovarian cancer	0.000165	0.000997	CcSEcCtD
Fluocinolone Acetonide—Nervous system disorder—Epirubicin—ovarian cancer	0.000163	0.000988	CcSEcCtD
Fluocinolone Acetonide—Dizziness—Docetaxel—ovarian cancer	0.000163	0.000988	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Adipogenesis—IL6ST—ovarian cancer	0.000162	0.00289	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—APC—ovarian cancer	0.000162	0.00288	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Phospholipid metabolism—PIK3CB—ovarian cancer	0.000161	0.00286	CbGpPWpGaD
Fluocinolone Acetonide—Arthralgia—Doxorubicin—ovarian cancer	0.000161	0.000973	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Glucocorticoid receptor regulatory network—IL2—ovarian cancer	0.000158	0.00282	CbGpPWpGaD
Fluocinolone Acetonide—Vomiting—Docetaxel—ovarian cancer	0.000157	0.00095	CcSEcCtD
Fluocinolone Acetonide—Rash—Docetaxel—ovarian cancer	0.000155	0.000942	CcSEcCtD
Fluocinolone Acetonide—Dermatitis—Docetaxel—ovarian cancer	0.000155	0.000941	CcSEcCtD
Fluocinolone Acetonide—Headache—Docetaxel—ovarian cancer	0.000154	0.000936	CcSEcCtD
Fluocinolone Acetonide—Oedema—Doxorubicin—ovarian cancer	0.000154	0.000932	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Fc-epsilon receptor I signaling in mast cells—AKT1—ovarian cancer	0.000154	0.00274	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—SPARC—ovarian cancer	0.000153	0.00273	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	0.000153	0.00273	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Gene Expression—WDR77—ovarian cancer	0.000153	0.00272	CbGpPWpGaD
Fluocinolone Acetonide—Infection—Doxorubicin—ovarian cancer	0.000153	0.000926	CcSEcCtD
Fluocinolone Acetonide—Musculoskeletal discomfort—Epirubicin—ovarian cancer	0.000152	0.000918	CcSEcCtD
Fluocinolone Acetonide—Nervous system disorder—Doxorubicin—ovarian cancer	0.000151	0.000914	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—PDGFR-beta signaling pathway—PTEN—ovarian cancer	0.00015	0.00268	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Endothelins—AKT1—ovarian cancer	0.00015	0.00267	CbGpPWpGaD
Fluocinolone Acetonide—Nausea—Docetaxel—ovarian cancer	0.000146	0.000888	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—AGE/RAGE pathway—AKT1—ovarian cancer	0.000145	0.00257	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Platelet activation, signaling and aggregation—PIK3CG—ovarian cancer	0.000144	0.00256	CbGpPWpGaD
Fluocinolone Acetonide—Gastrointestinal disorder—Epirubicin—ovarian cancer	0.000144	0.00087	CcSEcCtD
Fluocinolone Acetonide—Pain—Epirubicin—ovarian cancer	0.000142	0.000862	CcSEcCtD
Fluocinolone Acetonide—NR3C1—FOXA2 and FOXA3 transcription factor networks—AKT1—ovarian cancer	0.000141	0.00252	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—AP-1 transcription factor network—MYC—ovarian cancer	0.000141	0.0025	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—DLC1—ovarian cancer	0.000141	0.0025	CbGpPWpGaD
Fluocinolone Acetonide—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	0.00014	0.00085	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Phospholipid metabolism—PTEN—ovarian cancer	0.000139	0.00247	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—PDGFR-beta signaling pathway—STAT3—ovarian cancer	0.000135	0.0024	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—PDGFR-beta signaling pathway—NRAS—ovarian cancer	0.000134	0.00239	CbGpPWpGaD
Fluocinolone Acetonide—Gastrointestinal disorder—Doxorubicin—ovarian cancer	0.000133	0.000805	CcSEcCtD
Fluocinolone Acetonide—Pain—Doxorubicin—ovarian cancer	0.000132	0.000797	CcSEcCtD
Fluocinolone Acetonide—Body temperature increased—Epirubicin—ovarian cancer	0.000131	0.000797	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Generic Transcription Pathway—YAP1—ovarian cancer	0.000129	0.0023	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—PDGFR-beta signaling pathway—MAPK3—ovarian cancer	0.000129	0.00229	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Glucocorticoid receptor regulatory network—MAPK3—ovarian cancer	0.000127	0.00227	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Platelet activation, signaling and aggregation—PIK3CD—ovarian cancer	0.000127	0.00225	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—ERBB2—ovarian cancer	0.000126	0.00224	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—MYC—ovarian cancer	0.000125	0.00223	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—PDGFR-beta signaling pathway—MYC—ovarian cancer	0.000125	0.00223	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	0.000125	0.00223	CbGpPWpGaD
Fluocinolone Acetonide—Hypersensitivity—Epirubicin—ovarian cancer	0.000123	0.000743	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—PDGFR-beta signaling pathway—MAPK1—ovarian cancer	0.000122	0.00218	CbGpPWpGaD
Fluocinolone Acetonide—Body temperature increased—Doxorubicin—ovarian cancer	0.000122	0.000737	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Glucocorticoid receptor regulatory network—MAPK1—ovarian cancer	0.000121	0.00216	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Gene Expression—TTF1—ovarian cancer	0.00012	0.00214	CbGpPWpGaD
Fluocinolone Acetonide—Pruritus—Epirubicin—ovarian cancer	0.000118	0.000713	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Metabolism—CYTB—ovarian cancer	0.000116	0.00207	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—CDKN1B—ovarian cancer	0.000116	0.00207	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—AP-1 transcription factor network—TP53—ovarian cancer	0.000116	0.00206	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—PDGFR-beta signaling pathway—KRAS—ovarian cancer	0.000116	0.00206	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—BCL9—ovarian cancer	0.000115	0.00204	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—CASP3—ovarian cancer	0.000114	0.00203	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	0.000114	0.00203	CbGpPWpGaD
Fluocinolone Acetonide—Diarrhoea—Epirubicin—ovarian cancer	0.000114	0.00069	CcSEcCtD
Fluocinolone Acetonide—Hypersensitivity—Doxorubicin—ovarian cancer	0.000113	0.000687	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Generic Transcription Pathway—PGR—ovarian cancer	0.000113	0.00201	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—SOD1—ovarian cancer	0.000111	0.00198	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—CCND1—ovarian cancer	0.000111	0.00198	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—PPP2R1A—ovarian cancer	0.000111	0.00197	CbGpPWpGaD
Fluocinolone Acetonide—Dexamethasone—ABCB1—ovarian cancer	0.000111	0.0326	CrCbGaD
Fluocinolone Acetonide—PLA2G4A—Platelet activation, signaling and aggregation—PIK3CB—ovarian cancer	0.00011	0.00196	CbGpPWpGaD
Fluocinolone Acetonide—Dizziness—Epirubicin—ovarian cancer	0.00011	0.000666	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—CTNNB1—ovarian cancer	0.00011	0.00196	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Gene Expression—NR5A1—ovarian cancer	0.000109	0.00194	CbGpPWpGaD
Fluocinolone Acetonide—Pruritus—Doxorubicin—ovarian cancer	0.000109	0.00066	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—PTEN—ovarian cancer	0.000107	0.00191	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—PDGFR-beta signaling pathway—PIK3CA—ovarian cancer	0.000106	0.00189	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Adipogenesis—CTNNB1—ovarian cancer	0.000106	0.00188	CbGpPWpGaD
Fluocinolone Acetonide—Vomiting—Epirubicin—ovarian cancer	0.000106	0.000641	CcSEcCtD
Fluocinolone Acetonide—NR3C1—AP-1 transcription factor network—IL6—ovarian cancer	0.000106	0.00188	CbGpPWpGaD
Fluocinolone Acetonide—Diarrhoea—Doxorubicin—ovarian cancer	0.000105	0.000638	CcSEcCtD
Fluocinolone Acetonide—Rash—Epirubicin—ovarian cancer	0.000105	0.000635	CcSEcCtD
Fluocinolone Acetonide—Dermatitis—Epirubicin—ovarian cancer	0.000105	0.000635	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Generic Transcription Pathway—PARP1—ovarian cancer	0.000105	0.00187	CbGpPWpGaD
Fluocinolone Acetonide—Headache—Epirubicin—ovarian cancer	0.000104	0.000631	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Metabolism—BRIP1—ovarian cancer	0.000102	0.00181	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—PPP1CC—ovarian cancer	0.000102	0.00181	CbGpPWpGaD
Fluocinolone Acetonide—Dizziness—Doxorubicin—ovarian cancer	0.000102	0.000617	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Glucocorticoid receptor regulatory network—TP53—ovarian cancer	0.000102	0.00181	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Platelet activation, signaling and aggregation—IL2—ovarian cancer	0.000101	0.0018	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—SIDS Susceptibility Pathways—CXCL8—ovarian cancer	9.91e-05	0.00177	CbGpPWpGaD
Fluocinolone Acetonide—Nausea—Epirubicin—ovarian cancer	9.88e-05	0.000599	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—PDGFR-beta signaling pathway—HRAS—ovarian cancer	9.82e-05	0.00175	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Phospholipid metabolism—PIK3CA—ovarian cancer	9.8e-05	0.00175	CbGpPWpGaD
Fluocinolone Acetonide—Vomiting—Doxorubicin—ovarian cancer	9.79e-05	0.000593	CcSEcCtD
Fluocinolone Acetonide—Rash—Doxorubicin—ovarian cancer	9.7e-05	0.000588	CcSEcCtD
Fluocinolone Acetonide—Dermatitis—Doxorubicin—ovarian cancer	9.7e-05	0.000587	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—VEGFA—ovarian cancer	9.68e-05	0.00172	CbGpPWpGaD
Fluocinolone Acetonide—Headache—Doxorubicin—ovarian cancer	9.64e-05	0.000584	CcSEcCtD
Fluocinolone Acetonide—NR3C1—SIDS Susceptibility Pathways—CASP3—ovarian cancer	9.49e-05	0.00169	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Glucocorticoid receptor regulatory network—IL6—ovarian cancer	9.32e-05	0.00166	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Adipogenesis—STAT3—ovarian cancer	9.23e-05	0.00164	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—MAPK3—ovarian cancer	9.16e-05	0.00163	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—SIDS Susceptibility Pathways—CTNNB1—ovarian cancer	9.15e-05	0.00163	CbGpPWpGaD
Fluocinolone Acetonide—Nausea—Doxorubicin—ovarian cancer	9.14e-05	0.000554	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—DOK1—ovarian cancer	9.05e-05	0.00161	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—MYC—ovarian cancer	8.91e-05	0.00159	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—MAPK1—ovarian cancer	8.71e-05	0.00155	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—EGFR—ovarian cancer	8.71e-05	0.00155	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—AKT1—ovarian cancer	8.68e-05	0.00155	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Platelet activation, signaling and aggregation—VEGFA—ovarian cancer	8.61e-05	0.00153	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Glucocorticoid receptor regulatory network—AKT1—ovarian cancer	8.59e-05	0.00153	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—PPP1CC—ovarian cancer	8.51e-05	0.00152	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—KRAS—ovarian cancer	8.23e-05	0.00147	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—CAV1—ovarian cancer	8.15e-05	0.00145	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Platelet activation, signaling and aggregation—MAPK3—ovarian cancer	8.15e-05	0.00145	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—SIDS Susceptibility Pathways—VEGFA—ovarian cancer	8.05e-05	0.00143	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Platelet activation, signaling and aggregation—MAPK1—ovarian cancer	7.75e-05	0.00138	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—PIK3CA—ovarian cancer	7.56e-05	0.00135	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—PIK3CG—ovarian cancer	7.42e-05	0.00132	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	7.42e-05	0.00132	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—TP53—ovarian cancer	7.31e-05	0.0013	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—YAP1—ovarian cancer	6.83e-05	0.00122	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	6.76e-05	0.0012	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Platelet activation, signaling and aggregation—PIK3CA—ovarian cancer	6.73e-05	0.0012	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—PIK3CD—ovarian cancer	6.53e-05	0.00116	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—HDAC6—ovarian cancer	6.45e-05	0.00115	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Adipogenesis—IL6—ovarian cancer	6.44e-05	0.00115	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—PPP2R1A—ovarian cancer	6.36e-05	0.00113	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Gene Expression—YAP1—ovarian cancer	6.21e-05	0.00111	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—AKT1—ovarian cancer	6.18e-05	0.0011	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Generic Transcription Pathway—ESR1—ovarian cancer	6.02e-05	0.00107	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	5.94e-05	0.00106	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—YAP1—ovarian cancer	5.71e-05	0.00102	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—PIK3CB—ovarian cancer	5.69e-05	0.00101	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—XIAP—ovarian cancer	5.59e-05	0.000996	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—SIDS Susceptibility Pathways—IL6—ovarian cancer	5.57e-05	0.000992	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—FASN—ovarian cancer	5.57e-05	0.000991	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Platelet activation, signaling and aggregation—AKT1—ovarian cancer	5.5e-05	0.000978	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—SLC5A5—ovarian cancer	5.48e-05	0.000975	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—SMARCA4—ovarian cancer	5.45e-05	0.000971	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Gene Expression—PGR—ovarian cancer	5.43e-05	0.000966	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—EREG—ovarian cancer	5.32e-05	0.000947	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—SLC2A1—ovarian cancer	5.29e-05	0.000942	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—IL2—ovarian cancer	5.22e-05	0.00093	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	5.18e-05	0.000922	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—CYP1B1—ovarian cancer	5.07e-05	0.000903	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Gene Expression—PARP1—ovarian cancer	5.04e-05	0.000898	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—PGR—ovarian cancer	4.99e-05	0.000888	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—PARP1—ovarian cancer	4.64e-05	0.000825	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—PPP2R1A—ovarian cancer	4.5e-05	0.000801	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	4.47e-05	0.000797	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—VEGFA—ovarian cancer	4.44e-05	0.00079	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—IL6ST—ovarian cancer	4.43e-05	0.000789	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—NRAS—ovarian cancer	4.39e-05	0.000781	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—PIK3CG—ovarian cancer	4.26e-05	0.000759	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—MAPK3—ovarian cancer	4.2e-05	0.000748	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—ABCB1—ovarian cancer	4.18e-05	0.000743	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—TYMS—ovarian cancer	4.1e-05	0.00073	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Gene Expression—PPP2R1A—ovarian cancer	4.09e-05	0.000729	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—MAPK1—ovarian cancer	4e-05	0.000712	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—KRAS—ovarian cancer	3.77e-05	0.000672	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—PPP2R1A—ovarian cancer	3.76e-05	0.000669	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—PIK3CD—ovarian cancer	3.75e-05	0.000667	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—PIK3CA—ovarian cancer	3.47e-05	0.000617	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—TP53—ovarian cancer	3.35e-05	0.000597	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—CAV1—ovarian cancer	3.3e-05	0.000588	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—PIK3CB—ovarian cancer	3.26e-05	0.000581	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—HRAS—ovarian cancer	3.21e-05	0.000571	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	3.16e-05	0.000562	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—CXCL8—ovarian cancer	3.14e-05	0.000559	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Generic Transcription Pathway—MYC—ovarian cancer	3.13e-05	0.000557	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—PIK3CG—ovarian cancer	3.01e-05	0.000536	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—IL2—ovarian cancer	3e-05	0.000534	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—TERT—ovarian cancer	2.99e-05	0.000532	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Gene Expression—ESR1—ovarian cancer	2.9e-05	0.000516	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—AKT1—ovarian cancer	2.83e-05	0.000504	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—CAV1—ovarian cancer	2.76e-05	0.000492	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—ESR1—ovarian cancer	2.66e-05	0.000474	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—PIK3CD—ovarian cancer	2.65e-05	0.000471	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—IL6ST—ovarian cancer	2.62e-05	0.000466	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—APC—ovarian cancer	2.52e-05	0.000448	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—PIK3CG—ovarian cancer	2.52e-05	0.000448	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—NRAS—ovarian cancer	2.52e-05	0.000448	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—MAPK3—ovarian cancer	2.41e-05	0.000429	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—PIK3CB—ovarian cancer	2.31e-05	0.000411	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—MAPK1—ovarian cancer	2.29e-05	0.000408	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—EGFR—ovarian cancer	2.29e-05	0.000408	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—PIK3CD—ovarian cancer	2.21e-05	0.000394	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—KRAS—ovarian cancer	2.17e-05	0.000386	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—PTEN—ovarian cancer	1.99e-05	0.000355	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—PIK3CA—ovarian cancer	1.99e-05	0.000354	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—ERBB2—ovarian cancer	1.95e-05	0.000348	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—MTOR—ovarian cancer	1.93e-05	0.000343	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—PIK3CB—ovarian cancer	1.93e-05	0.000343	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—CXCL8—ovarian cancer	1.85e-05	0.00033	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—HRAS—ovarian cancer	1.84e-05	0.000328	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—CDKN1B—ovarian cancer	1.81e-05	0.000322	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—CASP3—ovarian cancer	1.77e-05	0.000316	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—IL2—ovarian cancer	1.77e-05	0.000315	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—IL6—ovarian cancer	1.76e-05	0.000314	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—CCND1—ovarian cancer	1.73e-05	0.000307	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—CTNNB1—ovarian cancer	1.71e-05	0.000304	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—MMP9—ovarian cancer	1.68e-05	0.000298	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—PTEN—ovarian cancer	1.67e-05	0.000297	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—AKT1—ovarian cancer	1.63e-05	0.000289	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Gene Expression—MAPK3—ovarian cancer	1.55e-05	0.000276	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Gene Expression—MYC—ovarian cancer	1.51e-05	0.000268	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—VEGFA—ovarian cancer	1.51e-05	0.000268	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—STAT3—ovarian cancer	1.49e-05	0.000265	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—NRAS—ovarian cancer	1.49e-05	0.000265	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—MAPK3—ovarian cancer	1.42e-05	0.000254	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—PIK3CA—ovarian cancer	1.41e-05	0.00025	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—MYC—ovarian cancer	1.38e-05	0.000247	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—MAPK1—ovarian cancer	1.35e-05	0.000241	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—EGFR—ovarian cancer	1.35e-05	0.000241	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—KRAS—ovarian cancer	1.28e-05	0.000228	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—PIK3CA—ovarian cancer	1.18e-05	0.000209	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—AKT1—ovarian cancer	1.15e-05	0.000204	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—TP53—ovarian cancer	1.14e-05	0.000202	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—HRAS—ovarian cancer	1.09e-05	0.000194	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Gene Expression—AKT1—ovarian cancer	1.05e-05	0.000186	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—IL6—ovarian cancer	1.04e-05	0.000185	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—AKT1—ovarian cancer	9.6e-06	0.000171	CbGpPWpGaD
